Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
GlobeNewswire
*At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71% overall..